Brief: Newron Pharmaceuticals To Request Type A FDA Meeting

Newron Pharmaceuticals SpA

09/12/2019 16:50

Dec 9 (Reuters) - NEWRON PHARMACEUTICALS SPA  NWRN.S :
    * NEWRON PHARMACEUTICALS TO REQUEST TYPE A FDA MEETING PRIOR
TO
UNBLINDING OF STARS CLINICAL TRIAL DATA
    * MEETING EXPECTED TO OCCUR WITHIN THIRTY DAYS OF FDA'S
RECEIPT OF
MEETING REQUEST AND MEETING PACKAGE
    * STARS (SARIZOTAN TREATMENT OF APNEAS IN RETT SYNDROME)
CLINICAL
STUDY TO EVALUATE EFFECT OF SARIZOTAN IN PATIENTS WITH RETT
SYNDROME
    * STARS EXTENSION STUDY UNDERWAY WITH OVER 80% OF PATIENTS
RECEIVING MEDICATION

Source text for Eikon:  ID:nEQ5cMsJ4a 
Further company coverage:  NWRN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))